Risperdal Fact Sheet
Janssen, market exclusivity expires 2008.
Schizophrenia, both acute and maintenance treatment.
- Bipolar disorder, including manic or mixed episodes, as both monotherapy and combination treatment with lithium or Depakote.
- Common off-label use for augmentation for depression and anxiety.
D2 and 5HT 2 receptor antagonist.
- Tablets in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg
- Orally disintegrating “M-Tabs” in 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg
- Oral solution (1 mg/ml) in 30 ml bottles
- Risperdal Consta is a long-acting injectable formulation which is dosed at 25 mg IM Q 2 weeks.
- Dosing variable depending on population. Generally, start at 1-2 mg QD or QHS, advancing to 2 mg BID as needed. Increase to 6 mg QD only if necessary, since EPS is highly dose dependent.
- Initial dose in elderly patients and those with severe renal or hepatic impairment is 0.5 mg BID.
BLACK BOX WARNING: All atypicals may increase mortality in elderly patients by 1.7 times greater than placebo.
- Most common are EPS, somnolence, anxiety, constipation, nausea, and dyspepsia.
- EPS: More frequent with Risperdal than any other atypical; occurs much less commonly at lower dosages.
- Weight gain: Can be significant, 18% of patients receiving Risperdal in 8-week trials gained at least 7% of their baseline body weight, and the average gain for children in 12-month trials was over 16 pounds.
- Glucose/Lipids: Causes diabetes infrequently, probably at a lower rate than Zyprexa.
- EKG: No concerns.
- Prolactin level: Causes the most hyperprolactinemia of all the atypicals. Symptoms in women are galactorrhea, amenorrhea, breast engorgement; in men, gynecomastia and lowered libido.
- Pregnancy Category C
Does not significantly affect the metabolism of other drugs.
- Since Risperdal is metabolized by CYP2D6, Tegretol and other enzyme inducers decrease effective dose, Prozac and Paxil increase levels of Risperdal.
Metabolized by CYP2D6 to an active metabolite, 9-hydroxyrisperidone.
- Half-life is about 20 hours.
Earn CME Credit Instantly!
Already an A la Carte subscriber? Click here to go to your a la carte page
Steve Balt Interviewed by NPR
The 2012 Carlat Atypical Antipsychotics Table is Now Available!
TCPR Continuing Education